'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease?

International Journal of Epidemiology

Volumn 32, Issue 1, 2003, Pages 1-22

  Smith, George D ^a   Ebrahim, Shah ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; CLINICAL OBSERVATION; CONCEPTION; DEVELOPMENT; DISEASE PREDISPOSITION; EDITORIAL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GAMETE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; INFORMATION PROCESSING; PARENT; PHENOTYPE; PREVENTION; PRIORITY JOURNAL; PROGENY; RANDOMIZATION;

ANIMALS; DISEASE; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY, MOLECULAR; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 0037322022     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyg070     Document Type: Editorial

References (175)

1. Butler D. Epidemiology set to get fast-track treatment. Nature 2001; 414:139.
2. Khoury MJ, Dorman JS. The human genome epidemiology network (HuGE Net) Am J Epidemiol 1998;148:1-3.
3. Khoury MJ. Human Genome Epidemiology (HuGE): translating advances in human genetics into population-based data for medicine and public health. Genet Med 1999;1:71-73.
4. Khoury MJ, Burke W, Thomson EJ (eds). Genetics and Public Health in the 21st Century. Oxford: Oxford University Press, 2000, pp. 10-11.
5. Porta M. The genome sequence is a jazz score. Int J Epidemiol 2003; 32:29-31.
6. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 201;357:709-12.
7. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986;i:507-08.
8. Ames BN. Cancer prevention and diet: Help from single nucleotide polymorphisms. PNAS 1999;96:12216-18.
9. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochimica Biophysica Acta 2001;1471:C1-C10.
10. Brennan P. Gene environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23:381-87.
11. Youngman LD, Keavney BD, Palmer A et al. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by 'Mendelian randomization'. Circulation 2000;102(Suppl.II):31-32.
12. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001; 358:1356-60.
13. Fallon UB, Ben-Shlomo Y, Davey Smith G. Homocysteine and coronary heart disease. Heart Online 14 March 2001 (http://heart.bmjjournals.com/cgi/eletters/85/2/153)
14. Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol 2002;31:730-36.
15. Davey Smith G, Ebrahim S. Data dredging, bias and confounding BMJ 2002;325:1437-38.
16. Feinstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science 1988;242:1257-63.
17. Taubes G. Epidemiology faces its limits. Science 1995;269:164-69.
18. Le Fanu J. The Rise and Fall of Modern Medicine. New York: Little Brown, 1999.
19. Skrabanek P. False Premises, False Promises. Whithorn: Tarragon Press, 2000.
20. Davey Smith G. Reflections on the limitations to epidemiology. J Clin Epidemiol 2001;54:325-31.
21. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290:201-08.
22. Willett WC. Vitamin A and lung cancer. Nutr Rev 1990;48:201-11.
23. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330: 1029-35.
24. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-55.
25. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-49.
26. Hooper L, Ness AR, Davey Smith G. Antioxidant strategy for cardiovascular diseases. Lancet 2001;357:1705-06.
27. Khaw K-T, Bingham S, Welch A et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet 2001; 357:657-63.
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-33.
29. Davey Smith G, Phillips AN. Confounding in epidemiological studies: why 'independent' effects may not be all they seem. BMJ 1992;305: 757-59.
30. Phillips A, Davey Smith G. How independent are 'independent' effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
31. Phillips AN, Davey Smith G. The design of prospective epidemiological studies: more subjects or better measurements? J Clin Epidemiol 1993; 46:1203-11.
32. Weiss NS. Can the 'specificity' of an association be rehabilitated as a basis for supporting a causal hypothesis? Epidemiology 2002;13:6-8.
33. Petitti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease. N Engl J Med 1986;315:131-32.
34. Phillips A. Balancing quantity and quality when designing epidemiological studies. Int J Epidemiol 2003;32:58-59.
35. Phillips AN, Davey Smith G. Cigarette smoking as a potential cause of cervical cancer: has confounding been controlled? Int J Epidemiol 1994;23:42-49.
36. Greenland S. Basic methods for sensitivity analysis. Int J Epidemiol 1996;25:1107-16.
37. Davey Smith G. The uses of 'The Uses of Epidemiology'. Int J Epidemiol 2001;30:1146-55.
38. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7(Suppl.3):9-12.
39. Ljungman P, De Witte T, Verdonck L et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993;84:61-66.
40. Keating S, de Witte T, Suciu S et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMENA. Br J Haematol 1998;102:1344-53.
41. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogenic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400.
42. Bleakley M, Shaw PJ, Nielsen JM. Allogenic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor. Bone Marrow Transplant 2002;31:1-7.
43. Harrison G, Richards S, Lawson S et al. on behalf of the MRC Childhood Leukaemia Working Party. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol 2000;11: 999-1006.
44. Mendel G. Experiments in Plant Hybridization (1865). http://www.mendelweb.org/archive/Mendel.Experiments.txt (accessed 12 Dec 2002).
45. Elston R, Olson J, Palmer L (eds). Biostatistical Genetics and Genetic Epidemiology. Chichester: John Wiley & Sons, 2002, p. 285.
46. Terwilliger JD, Goring HHH. Gene mapping in the 20th and 21st centuries: statistical methods, data analysis and experimental design. Hum Biol 2000;72:63-132.
47. Talking Glossary: National Human Genome Research Institute. www.genome.gov/glossary.cfm (accessed 12 Dec 2002).
48. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506-16.
49. Ahsan H, Hodge SE, Heiman GA, Begg MD, Susser ES. Relative risk for genetic associations: the case-parent triad as a variant of case-cohort design. Int J Epidemiol 2002;31:669-78.
50. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
51. Garcia-Palmiere MR, Sorlie PD, Costas R, Havlik RJ. An apparent inverse relationship between serum cholesterol and cancer mortality in Puerto Rico. Am J Epidemiol 1981;114:29-40.
52. McMichael AJ, Jensen OM, Parkin DM, Zaridze DG. Dietary and endogenous cholesterol and human cancer. Epidemiol Rev 1984;6:192-216.
53. Wessel N, Liestol K, Maehlen J, Brorson SH. The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population. Br J Cancer 2001;85:1418.
54. Niemi M, Kervinen K, Kiviniemi H et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 2000;54:938-39.
55. Moysich KB, Freudenheim JL, Baker JA et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog 2000;27:2-9.
56. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
57. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized controlled trials. BMJ 1998;316:894-98.
58. Brattström L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
59. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
60. Clarke R. An updated review of the published studies of homocysteine and cardiovascular disease. Int J Epidemiol 2002;31:70-71.
61. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12 and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA 2002;288:973-79.
62. Schnyder G, Roffi M, Flammer Y et al. Decreased rate of coronary restenosis with lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
63. Vermeulen E. Stehouwer C, Twisk J et al. Effect of homocysteine lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized placebo controlled trial. Lancet 2000;355:517-22.
64. Brattström L, Wilcken D, Öhrvik J, Brudin L. Common methylene-tetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-26.
65. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002;288: 2015-22.
66. Klerk M, Verhoef P, Clarke R et al. MTHFR 677C→T polymorphism and risk of coronary heart disease. A meta-analysis. JAMA 2002;288: 2023-31.
67. Clarke R, Lewington S, Donald A et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001;8:363-69.
68. Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 2000;71(Suppl.):1295S-303S.
69. MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council vitamin study. Lancet 1991;338:131-37.
70. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. New Engl J Med 1992;327:1832-35.
71. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE Review. Am J Epidemiol 2000;151:862-77.
72. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM et al. Maternal hyperhomocysteinemia: a risk factor for neural tube defects? Metabolism 1994;43:1475-80.
73. Rosenquist TH, Finnell RH. Genes, folate and homocysteine in embryonic development. Proc Nutr Soc 2001;60:53-61.
74. Mills JL, McPartlin MJ, Kirke PN et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345: 149-51.
75. Andersson A, Hultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30: 377-79.
76. Anonymous. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991;338:131-37.
77. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr 2000;71:962-68.
78. Marugame T, Tsuji E, Kiyohara C et al. Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal cancer. Int J Epidemiol 2003;32:64-66.
79. Fallon UB. Colon cancer, folate and genetic status. Int J Epidemiol 2003;32:67-70.
80. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57-67.
81. Houlston RS, Tomlinson IPM. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301.
82. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002;13:239-48.
83. Franco RF, Simões BP, Tone LG, Gabellini SM, Zago MA, Falcão. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 2001;115:616-18.
84. Skibola CF, Smith MT, Kane E et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96:12810-15.
85. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-82.
86. Marmot M. Commentary: Reflections on alcohol and coronary heart disease. Int J Epidemiol 2001;30:729-34.
87. Bovet P, Paccaud F. Commentary: Alcohol, coronary heart disease and public health: which evidence-based policy? Int J Epidemiol 2001;30:734-37.
88. Klatsky AL. Commentary: Could abstinence from alcohol be hazardous to your health? Int J Epidemiol 2001;30:739-42.
89. Shaper AG. Editorial: alcohol, the heart, and health. Am J Public Health 1993;83:799-801.
90. Hart CL, Davey Smith G, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ 1999;318:1725-29.
91. Rimm E. Commentary: Alcohol and coronary heart disease-laying the foundation for future work. Int J Epidemiol 2001;30:738-39.
92. Eriksson CJP, Fukunaga T, Sarkola T et al. Functional relevance of human ADH polymorphism. Alcohol Clin Exp Res 2001;25:157S-63S.
93. Agarwal DP. Genetic polymorphisms of alcohol metabolizing enzymes. Pathol Biol 2001;49:703-09.
94. Whitfield JB, Nightingale BN, Bucholz KK, Madden PAF, Heath AC, Martin NG. ADH Genotypes and alcohol use and dependence in Europeans. Alcohol Clin Exp Res 1998;22:1463-69.
95. Hines LM, Stampfer MJ, Ma J et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med 2001;344: 549-55.
96. Tadel M, Goldman D. Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism. Drug Metabolism and Disposition 2001;29: 489-94.
97. Sun F, Tsuritani I, Yamada Y. Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem drinking behavior in middle-aged Japanese men. Behav Genet 2002;32:229-36.
98. Nakamura Y, Amamoto K, Tamaki S et al. Genetic variation in aldehyde dehydrogenase 2 and the effect of alcohol consumption on cholesterol levels. Atherosclerosis 2002;164:171-77.
99. Haskell WL, Camargo C, Williams PT et al. The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfractions. N Engl J Med 1984;310:805-10.
100. Burr ML, Fehily AM, Butland BK et al. Alcohol and high-density-lipoprotein cholesterol: a randomized controlled trial. Br J Nutr 1986;56:81-86.
101. Cherry N, Mackness M, Durrington P et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002;359:763-64.
102. D'Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996;1:149-73.
103. Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev 2000;9:29-42.
104. Vineis P, McMichael AJ. Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the aetiology of colon cancer. Cancer Causes Control 1996;7:479-86.
105. Roberts-Thomson I, Ryan PR, Khoo K et al. Diet, acetylator phenotype and risk of colorectal neoplasia. Lancet 1996;347: 1372-74.
106. Colhoun H, KcKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003, in press.
107. -455→A) in the β-Fibrinogen promoter is an independent predictor of plama fibrinogen, but not of ischaemic heart disease. J Clin Invest 1999:3034-39.
108. Van der Bom JG, De Maat MPM, Bots ML et al. Elevated plasma fibrinogen. Cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998;18:621-25.
109. Doggen CJM, Bertina RM, Manger Cats V, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000;110:935-38.
110. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998;279:1477-82.
111. Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O'Brien J. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996;347:1008-13.
112. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
113. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
114. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. The coronary drug project research group. JAMA 1975;231:360-80.
115. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325:1139.
116. Ebrahim S, Davey Smith G, McCabe C et al. Cholesterol and coronary heart disease: screening and treatment. Qual Health Care 1998;7:232-39.
117. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-96.
118. Hallman DM, Boerwinkle E, Saha N et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338-49.
119. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 2000;41:1812-22.
120. Keavney BD, Youngman LD, Palmer A et al. Large-scale test of hypothesized associations between polymorphisms of lipid-related genes and myocardial infarction in about 5000 cases and 6000 controls. Circulation 2000;102(Suppl.II):852.
121. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988:8:1-21.
122. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
123. Smith J. Apolipoproteins and aging: emerging mechanisms. Ageing Research Reviews 2002;1:345-65.
124. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE Review. Am J Epidemiol 2002;155:487-95.
125. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. Arterioscl Thromb Vasc Biol 1996;16:1250-55.
126. http://www.ncbi.nlm.nih.gov/Omim (accessed 12 Dec 2002).
127. http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html (accessed 12 Dec 2002).
128. http://hgvbase.cgb.ki.se/about.htm (accessed 12 Dec 2002).
129. Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 1997;66:606-10.
130. Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999;145:287-92.
131. Delanghe J, Cambier B, Langlois M et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 1997;132:215-19.
132. De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001;157:161-66.
133. Cardon LR, Bell JI. Association study designs for complex diseases. Nature Rev: Genetics 2001;2:91-99.
134. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000;92:1151-58.
135. Wacholder S, Rothman N, Caporaso N. Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomark Prev 2002;11:513-520.
136. Cardon LR, Palmer LJ. Wagging the dog? Population stratification and spurious allelic association. Lancet 2003;361:598-604.
137. Sijbrands EJG, Westengorp RGJ, Defesche JC, De Meier PHEM, Smelt AHM, Kastelein JJP. Mortality over two centuries in large pedigrees with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-23.
138. Pimstone SN, Sun X-M, Du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:309-15.
139. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genetics 2002;3:391-97.
140. Stephens JC, Schneider JA, Tanguay DA et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293:489-93.
141. Osier MV, Pakstis AJ, Soodyall H et al. A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet 2002;71:84-99.
142. Glebart WM. Databases in genomic research. Science 1998;282: 659-61.
143. Waddington CH. Canalization of development and the inheritance of acquired characteristics. Nature 1942;150:563-65.
144. Wilkins AS. Canalization: a molecular genetic perspective. BioEssays 1997;19:257-62.
145. Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. BioEssays 2000;22: 1095-105.
146. Gibson G, Wagner G. Canalization in evoluationary genetics: a stabilizing theory? BioEssays 2000;22:372-80.
147. Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science 2001;291:1001-04.
148. Debat V, David P. Mapping phenotypes: canalization, plasticity and developmental stability. Trends in Ecology and Evolution 2001;16: 555-61.
149. Kitami T, Nadeau JH. Biochemical networking contributes more to genetic buffering in human and mouse metabolic pathways than does gene duplication. Nature Genet 2002;32:191-94.
150. Gu Z, Steinmetz LM, Gu X, Scharfe C, Davis RW, Li W-H. Role of duplicate genes in genetic robustness against null mutations. Nature 2003;421:63-66.
151. Morange M. The Misunderstood Gene. Cambridge: Harvard University Press, 2001.
152. Bolon B, Galbreath E. Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio. Int J Toxicol 2002;21:55-64.
153. Gerlai R. Gene targeting: technical confounds and potential solutions in behavioural and brain research. Behavioural Brain Research 2001;125:13-21.
154. Williams RS, Wagner PD. Transgenic animals in integrative biology: approaches and interpretations of outcome. J Appl Physiol 2000; 88:1119-26.
155. Garry DJ, Ordway GA, Lorenz JN, Radford ER, Chin RW, Grange R et al. Mice without myoglobin. Nature 1998;395:905-08.
156. Gabriel SE, Jaakimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115: 787-96.
157. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci, USA 1999;96:7563-68.
158. Langenbach R, Morham SG, Tiano HF et al. Prostaglandin synthase gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83: 483-92.
159. De Witt D, Smith WL. Yes, but do they still get headaches? Cell 1995;83:345-48.
160. Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defense. Journal of Physiology - Paris 2001;95:3-9.
161. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. British Journal of Pharmacology 2001;132:1565-73.
162. Wright AF, Carothers AD, Campbell H. Gene-environment interactions-the BioBank UK study. Pharmacogenomics Journal 2002;2:75-82.
163. Weiss K, Terwilliger J. How many diseases does it take to map a gene with SNPs? Nat Genet 2000;26:151-57.
164. Erichsen HC, Eck P, Levine M, Chanock S. Characterization of the genomic structure of the human vitamin C transporter SVCT1 (SLC23A2). J Nutr 2001;131:2623-27.
165. Perera FP. Environment and cancer: who are susceptible? Science 1997;278:1068-73.
166. Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami HO. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. Journal of Internal Medicine 2001;249:477-93.
167. Chen J, Stampfer MJ, Hough HL et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998;58:3307-11.
168. Kampman E, Slattery ML, Bigler J et al. Meat consumption, genetic susceptibility, and colon cancer risk: a United States multi-center case-control study. Cancer Epidemiol Biomarkers Prev 1999;8:15-24.
169. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997;18:1351-54.
170. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin survival Study (4S). Lancet 1994;344:1383-89.
171. Heart Protection Study Collaborative Group. MRC/BHF heart protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals. Lancet 2002;360:7-22.
172. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-07.
173. Bateson W. Mendel's Principles of Heredity. Cambridge: Cambridge University Press, 1909.
174. Fisher RA. Has Mendel's work been rediscovered? Annals of Science 1936;1:115-37.
175. Sapp J. The nine lives of Gregor Mendel. In: Le Grand HE (ed.) Environmental Enquiries. London: Kluwer Academic Publishers, 1990, pp. 137-66.